COMPARISON OF PACLITAXEL AND DOCETAXEL (TAXOTERE) IN GYNECOLOGIC AND BREAST-CANCER CELL-LINES WITH THE ATP-CELL VIABILITY ASSAY

被引:33
作者
UNTCH, M
UNTCH, A
SEVIN, BU
ANGIOLI, R
PERRAS, JP
KOECHLI, O
AVERETTE, HE
机构
[1] UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,MIAMI,FL 33152
[2] UNIV ZURICH,FRAUENKLIN,CH-8006 ZURICH,SWITZERLAND
关键词
ANTI-MICROTUBULE AGENTS; ATP-CELL VIABILITY ASSAY; BREAST CANCER; DOCETAXEL; OVARIAN CANCER; PACLITAXEL;
D O I
10.1097/00001813-199402000-00004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The in vitro effects of paclitaxel (Tx) and docetaxel (Taxotere, Txt) are compared in this study using the adenosine triphosphate cell viability assay (ATP-CVA) in 14 cancer cell lines. Eleven cell lines were sensitive and three were partially sensitive to paclitaxel. Nine cell lines were sensitive, three were partially sensitive and two were resistant to docetaxel. Mean IC50s were 3.7-660 ng/ml paclitaxel and 5.4-540 ng/ml docetaxel. In five sensitive cancer cell lines docetaxel was more active than paclitaxel, and in six sensitive cell lines paclitaxel was more active than docetaxel on a concentration basis. Two cell lines were sensitive to paclitaxel and resistant to docetaxel. In one cell line the two compounds had similar activities. In the ATP-CVA, paclitaxel and docetaxel are very active and are partially non-cross-resistant.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 35 条
[1]  
AAPRO M, 1992, P AM SOC CLIN ONCOL, V35, P521
[2]  
BARASOAIN I, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P329
[3]  
BISSERY M C, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P401
[4]  
BISSERY MC, 1991, CANCER RES, V51, P4845
[5]   ANTITUMOR-ACTIVITY OF TAXOTERE (RP-56976, NSC-628503), A NEW TAXOL ANALOG, IN EXPERIMENTAL OVARIAN-CANCER [J].
BOVEN, E ;
VENEMAGABERSCEK, E ;
ERKELENS, CAM ;
BISSERY, MC ;
PINEDO, HM .
ANNALS OF ONCOLOGY, 1993, 4 (04) :321-324
[6]   PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR 6-HOUR INTRAVENOUS-INFUSION [J].
BURRIS, H ;
IRVIN, R ;
KUHN, J ;
KALTER, S ;
SMITH, L ;
SHAFFER, D ;
FIELDS, S ;
WEISS, G ;
ECKARDT, J ;
RODRIGUEZ, G ;
RINALDI, D ;
WALL, J ;
COOK, G ;
SMITH, S ;
VREELAND, F ;
BAYSSAS, M ;
LEBAIL, N ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :950-958
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]  
GAREWAL HS, 1986, J NATL CANCER I, V77, P1039
[9]   CHARACTERIZATION OF INVITRO CHEMOSENSITIVITY OF PERIOPERATIVE HUMAN OVARIAN MALIGNANCIES BY ADENOSINE-TRIPHOSPHATE CHEMOSENSITIVITY ASSAY [J].
GERHARDT, RT ;
PERRAS, JP ;
SEVIN, BU ;
PETRU, E ;
RAMOS, R ;
GUERRA, L ;
AVERETTE, HE .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (02) :245-255
[10]   RELATIONSHIPS BETWEEN THE STRUCTURE OF TAXOL ANALOGS AND THEIR ANTIMITOTIC ACTIVITY [J].
GUERITTEVOEGELEIN, F ;
GUENARD, D ;
LAVELLE, F ;
LEGOFF, MT ;
MANGATAL, L ;
POTIER, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (03) :992-998